Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study.
Martyn E. Caplin
Consultant or Advisory Role - Ipsen
Philippe B. Ruszniewski
Employment or Leadership Position - Ipsen (I)
Consultant or Advisory Role - Ipsen
Honoraria - Ipsen; Novartis
Research Funding - Ipsen; Novartis
Marianne E. Pavel
Consultant or Advisory Role - Ipsen; Lexicon; Novartis; Pfizer
Honoraria - Ipsen; Lexicon; Novartis; Pfizer
Research Funding - Novartis
Jaroslaw B. Cwikla
Research Funding - Ipsen
Alexandria T. Phan
Research Funding - Ipsen
Markus Raderer
Honoraria - Bayer; Celgene; Ipsen; Novartis; Pfizer; Roche
Eva Sedlackova
No relevant relationships to disclose
Guillaume Cadiot
Consultant or Advisory Role - Ipsen; Keocyt; Novartis
Honoraria - Ipsen; Keocyt; Novartis
Lucy R. Wall
No relevant relationships to disclose
Guido Rindi
Consultant or Advisory Role - Advanced Accelerator Applications; Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer
Alison Langley
Consultant or Advisory Role - Ipsen
Joelle Blumberg
Employment or Leadership Position - Ipsen